Compelling new studies curated by Ascendient ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­    ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  
View in browser
PHRR July 2026

Does the World Need Another Newsletter?

 

That's the question I wrestled with before we ever started putting together this issue of Research Roundup. I recognize that junk mail is an epidemic – and no one hates an epidemic more than public health professionals.

 

But eventually I came around to the idea, and here's why: Health departments are overworked and understaffed, leaving precious little time to sift through the mountain of new research that comes out every month. Even if you love research  and understand how important it is to your work, there's always something more urgent vying for your attention.

 

As consultants, however, keeping up with the latest research in not a luxury – it's literally at the heart of what we do. We thrive on digesting data and thinking through the implications for our clients. Countless conversations around our office start with something like: Hey, did you see the new study that said...?

 

Research Roundup is our attempt to let you in on those conversations. Each month, we'll highlight five studies we think are especially important to public health professionals, and we'll get beyond the numbers to suggest practical, actionable takeaways. We promise to keep every item short and punchy, with links to the source material if you'd like to know more. And if something really catches your eye, you can always follow up with us directly. We're as close as your "Reply" button.

Best,

Brian Ackerman

CEO

Brian Ackerman 1-1

POLICY and COMMS

Public Trust Levels Hold High for Vaccine Scientists

Despite years of sustained attacks on vaccine research, a nationally representative Annenberg Public Policy Center survey finds that public trust in vaccine scientists remains on par with trust in scientists generally. Nearly 7 in 10 Americans express at least a moderate level of trust in vaccine scientists. Lower-ranking messenger groups include: journalists (49%), religious leaders (47%), elected officials (36%), and business leaders (30%) all rank lower. Our Take: This reservoir of trust is real, but it requires active stewardship in a noisy information environment where communication gaps are quickly filled by misinformation. Silence is not a neutral position. LHDs should pick or build relationships with trusted spokespeople now, before a vaccine controversy hits, so they're not scrambling during a crisis.

OPERATIONS

Growing Evidence for Public Health Infrastructure Grants

A national evaluation of the CDC's Public Health Infrastructure Grant finds measurable gains across 107 health departments funded since 2022. At the program's midpoint, 73% of recipients were accredited or reaccredited, and 25% had completed reaccreditation since PHIG's launch. States like Missouri reported that over 80% of their LHDs are now on an accreditation pathway. Our Take: These gains are more than a compliance milestone. They align with the broader benefits accreditation is known to bring, including greater operational efficiency, access to funding, and credibility with policymakers and community partners. Accreditation progress is a concrete metric of public health value. LHDs should not treat it as a box to check, but as evidence-backed groundwork for long-term capacity building and sustainability.

DATA and SURVEILLANCE

Study Suggests 100% Undercount for Long Covid

A JAMA Network Open cohort study of nearly 458,000 patients across 58 hospitals found 16.3% of Covid-19 patients developed post-acute sequelae, double the rate captured by diagnostic codes and 89% chronic. That gap translates to more than 18 million Americans whose chronic conditions are invisible to current tracking systems. Our Take: This is a surveillance gap, not just a disease burden finding, and other chronic conditions may also be slipping through. LHDs cannot close the gap alone. State health agencies and academic partners with the analytic capacity to study clinical data at scale are better positioned to help. LHDs can push for assistance and data-modernization funding through existing state and regional partnerships, flagging where local disease burden may be undercounted.

POPULATION HEALTH2

New Data Support Greater Funding, Promotion for 988

A recent study in JAMA finds that suicide deaths among Americans ages 15 to 34 dropped 11% below projected rates in the two years after the 988 Suicide & Crisis Lifeline launched, with an 18% drop in states where call volume rose the most. The dose-response pattern suggests the lifeline is having a real population-level effect. Our Take: This is encouraging and actionable. Those most at risk remain least likely to call, so outreach should target higher-risk groups directly rather than relying on general awareness campaigns. Only 12 states have secured funding for 988 through phone-fee models (similar to 911 funding), so local advocates in other states have multiple policy options available, including promoting 988 and supporting state funding legislation.

COMM DISEASE

Shingles Vaccine Linked to Reduced Dementia Risk

An observational study in the Annals of Internal Medicine finds that nursing home residents age 66 and above who received at least one dose of the Shingrix shingles vaccine were 24% less likely to develop dementia over a four-year period, potentially preventing one in 17 cases. The findings add to a growing body of evidence linking viral infections to cognitive decline. Our Take: In a climate of vaccine skepticism, studies like this are strategic communication assets when framed carefully. Beyond disease prevention, LHD leaders can highlight unexpected vaccination benefits that broaden the pro-vaccine narrative beyond familiar talking points. Personal stories from older adults may be especially powerful in this regard.

 

Do you have a colleague who would enjoy reading our monthly Research Roundup? Please forward this issue and urge them to subscribe!

Did we miss something? If you've seen a public health research study that might be worth highlighting here, we're always open to suggestions. Just hit Reply to contact us.

Ascendient, 1335 Environ Way, Chapel Hill, NC 27517, 919-403-3300

Unsubscribe Manage preferences